Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05642767
Other study ID # Soh-Med-22-11-18
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 1, 2022
Est. completion date May 1, 2023

Study information

Verified date April 2023
Source Sohag University
Contact Noha S Shafik, lecturer
Phone 01067261504
Email Nohasaber@med.sohag.edu.eg
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Pseudomonas aeruginosa (PA) is a ubiquitous aerobic, non-fermentative Gram-negative rod that is widely associated with nosocomial pneumonia and can lead to severe illness with poor outcomes, particularly in critically ill people due to the ability of some strains to cause lung epithelial injury and spread into the circulation. 2 In the intensive care unit, PA infection is ranked among the top five causes of the bloodstream, pulmonary, surgical site, urinary tract, and soft tissue infections.


Description:

The pathogenesis of PA infections is multifactorial, and it is frequently complicated by the bacteria's intrinsic resistance to some antimicrobial agents such as sulfonamides, tetracyclines, and trimethoprim, as well as its ability to acquire or quickly develop resistance to major classes of antibiotics such as aminoglycosides, quinolones, B-lactams, and polymyxins (Bassetti et al., 2018). The efflux systems, which mediate the expulsion of antibiotics out of the cell shortly after entry, the production of enzymes to inactivate antibiotics, and the decrease in permeability across the cell wall are some mechanisms used by PA to develop antimicrobial resistance (Meletis & Bagkeri, 2013). PA possesses a large number of virulence factors that play a significant role in pathogenesis and the determination of infection severity. These virulence factors act alone or in synergy with each other to cause tissue damage, necrosis, and cell death. Among the virulence factors of PA, the major determinants of virulence are the type III secretion system (T3SS) and quorum sensing (cell-to-cell signaling system). The T3SS is a needle-like complex, also known as the injectisome, that enables a bacterium to deliver different effector proteins such as ExoS, ExoT, ExoU, and ExoY across the membrane into a host cell, altering host cell functions and increasing bacterial survival rates ( Horna G and, Ruiz J, 2021). In this study, we aimed to evaluate the prevalence of antibiotic resistance caused by the presence of Efflux genes and some virulence factors in Pseudomonas aeruginosa from clinical isolates.


Recruitment information / eligibility

Status Recruiting
Enrollment 75
Est. completion date May 1, 2023
Est. primary completion date March 30, 2023
Accepts healthy volunteers No
Gender All
Age group 4 Weeks to 80 Years
Eligibility Inclusion Criteria: - All patients suffering from infections that can be caused by pseudomonas aeruginosa Exclusion Criteria: - Samples diagnosed to have organisms other than pseudomonas aeruginosa.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
culture on cetrimide agar
Samples will be inoculated on cetrimide agar using the plating out technique.
Staining with Gram stain
colonies on cetrimide agar will be spread on glass slide and stained by gram stain
Antibiotic sensitivity testing
Antibiotic sensitivity testing will be done by disc diffusion method according to CLSI
Molecular detection to efflux genes and some virulence genes
Molecular detection to efflux genes and some virulence genes by conventional PCR

Locations

Country Name City State
Egypt Sohag University Sohag

Sponsors (1)

Lead Sponsor Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Isolation and identification of pseudomonas aeruginosa using culture and automated system techniques identification of pseudomonas aeruginosa in different clinical samples collected from Sohag University hospital using different laboratory techniques as culture on citramide agar, Staining with Gram, biochemical reactions such as Oxidase test, sugar fermentation test, and automated identification using vitek2 system 1 December 2022 to 1 February 2023
Primary Identification of recent antibiotic sensitivity pattern using Modified Kerby -Disc Diffusion method Determination of recent antibiotic sensitivity pattern using different antibiotics by disc diffusion method by spreading the inoculum in pitry dish containing Muller Hinton Agar, then different discs containing antibiotics are placed at a distance of 1.5 cm, then incubated at 37 co for 24 hrs. The diameter of the zone of inhibition is measured to determine MIC for each antibiotic according to the guidelines of CSLI 2022. 1 December 2022 to 1 February 2023
Primary Molecular Identification of some virulence factors and efflux genes using PCR Molecular detection of some virulence factors and efflux genes using specific primers by conventional PCR. primers of the following genes will be used as exoS,exoU, toxA, mex A, mex B. Extraction of DNA will be done first, followed by amplification technique using the thermal cycler. Detection of amplified DNA will be done using Agrose gel electrophoresis stained with ethidium bromide. 1 February 2023 to 30 March 2023
See also
  Status Clinical Trial Phase
Recruiting NCT04335383 - Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Not yet recruiting NCT06035055 - Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis Phase 4
Completed NCT00774072 - Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization Phase 2
Completed NCT00515229 - Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo Phase 2
Terminated NCT00333385 - Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Phase 4
Recruiting NCT03638830 - Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa Phase 2
Enrolling by invitation NCT05880069 - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Completed NCT00633191 - Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis Phase 1/Phase 2
Completed NCT00712166 - Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa Phase 3
Recruiting NCT04171817 - Animal-Assisted Visitation Program Chlorhexidine Trial Phase 4
Completed NCT02696902 - Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects Phase 2
Completed NCT01319253 - A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies N/A
Recruiting NCT05282082 - Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.
Recruiting NCT04803695 - Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT05632315 - PMT for MDRO Decolonization Phase 2
Completed NCT01055847 - Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection Phase 2
Completed NCT01745796 - Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia (PYO GEN)
Recruiting NCT04673175 - Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Terminated NCT05210387 - Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections N/A
Recruiting NCT05616221 - Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection Phase 2

External Links